Email updates

Keep up to date with the latest news and content from Virology Journal and BioMed Central.

Open Access Short report

siRNA against the G gene of human metapneumovirus

Faith Maxine Preston12, Claire P Straub12, Ruben Ramirez3, Suresh Mahalingam4 and Kirsten M Spann12*

Author Affiliations

1 Clinical Medical Virology Centre, The University of Queensland, Brisbane, QLD 4072, Australia

2 Sir Albert Sakzewski Virus Research Centre, Children’s Health Services, Brisbane, QLD 4029, Australia

3 Faculty of Applied Science, University of Canberra, Canberra, ACT 0200, Australia

4 Institute for Glycomics, Griffith University, Gold Coast, QLD 4222, Australia

For all author emails, please log on.

Virology Journal 2012, 9:105  doi:10.1186/1743-422X-9-105

Published: 7 June 2012

Abstract

Background

Human metapneumovirus (hMPV) is a significant viral respiratory pathogen of infants and children, the elderly and immunocompromised individuals. Disease associated with hMPV infection resembles that of human respiratory syncytial virus (RSV) and includes bronchiolitis and pneumonia. The glycosylated G attachment protein of hMPV is required for viral entry in vivo and has also been identified as an inhibitor of innate immune responses.

Findings

We designed and validated two siRNA molecules against the G gene using A549 cells and demonstrated consistent 88-92% knock-down for one siRNA molecule, which was used in subsequent experiments. Significant reduction of G mRNA in A549 cells infected with hMPV did not result in a reduction in viral growth, nor did it significantly increase the production of type I interferon (α/β) in response to infection. However, there was a moderate increase in IFN-β mRNA expression in response to infection in siG-transfected cells compared to untransfected and si-mismatch-transfected cells. Expression of G by recombinant adenovirus did not affect type I IFN expression.

Conclusion

G has been previously described as a type I interferon antagonist, although our findings suggest it may not be a significant antagonist.

Keywords:
siRNA; hMPV; Type I interferon